This page shows the latest GBI Research news and features for those working in and with pharma, biotech and healthcare.
And an even bigger threat is looming in the shape of Celgene’s ozanimod, a once-daily oral therapy that GBI Research has predicted could make rapid headway thanks to a
The use of mHealth will also be led by advances in mobile devices and network coverage, combined with falling prices for wireless technologies, according to GBI Research. ... Key drivers for mHealth uptake outlined in GBI Research’s new Mobile Health
Analysts at GBI Research expect the therapy area to achieve an annual growth rate of 7.2% over the next five years, almost doubling 2015's revenue total of $27.2bn. ... Qaisrah Khalid, an analyst at GBI Research, said: “There is a large pharmaceutical
research firm GBI.
GBI Research recently predicted that Ocaliva could become a blockbuster therapy by 2022.
That's according to GBI Research, which predicts an annual growth rate of 4.45% for the therapy area and expects Takeda to take over as market leader from AbbVie by ... biologics. Jennifer Goossens, associate analyst for GBI Research, said: “Due to the
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.
No results were found
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...